real-time news and commentary for investors
Monday, Oct 21
Cell Therapeutics says preclinical study shows Pixuvri is novel and distinct
- Cell Therapeutics (CTIC) says a preclinical study suggests Pixuvri's "mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin."
- Here's Dr. Neil Beeharry putting it In simpler terms: "The study results suggest that Pixuvri ... is the first approved drug in a new class of anti-cancer agents."
- Pixuvri is approved in the EU for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
- CTIC +2.7% premarket